Cargando…

Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe

In 2008, the European Union introduced the Advanced Medicines Regulation aiming to improve regulation of advanced therapy medicinal products (ATMPs). We applied the ATMPs classification definitions in this Regulation to understand the link of this emerging group of medicinal products and the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farkas, Andreas M., Mariz, Segundo, Stoyanova-Beninska, Violeta, Celis, Patrick, Vamvakas, Spiros, Larsson, Kristina, Sepodes, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432638/ https://www.ncbi.nlm.nih.gov/pubmed/28560211 http://dx.doi.org/10.3389/fmed.2017.00053

Ejemplares similares

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
por: Tomeo, Francesca, et al.
Publicado: (2021)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective
por: Sheean, Maria E., et al.
Publicado: (2021)

Editorial: The use of real world data for regulatory purposes in the rare diseases setting
por: Giannuzzi, Viviana, et al.
Publicado: (2022)

Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2015)

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
por: Polsinelli, Benedetta, et al.
Publicado: (2017)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
por: Eichler, Hans‐Georg, et al.
Publicado: (2020)

Editorial: Reviews in: regulatory science
por: Kerpel-Fronius, Sandor, et al.
Publicado: (2023)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
por: Eichler, Hans‐Georg, et al.
Publicado: (2019)

Use of biomarkers in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

Dose‐Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis
por: Schuller, Yvonne, et al.
Publicado: (2018)

Effectiveness of COVID-19 Vaccination Mandates and Incentives in Europe
por: Kuznetsova, Lidia, et al.
Publicado: (2022)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
por: Schuller, Yvonne, et al.
Publicado: (2018)

Making Sure That Orphan Incentives Tip the Right Way in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework
por: Carvalho, Marta, et al.
Publicado: (2017)

Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe
por: Sepodes, Bruno, et al.
Publicado: (2021)

Unlocking the potential of established products: toward new incentives rewarding innovation in Europe
por: Nayroles, Gabrielle, et al.
Publicado: (2017)

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach
por: Mulder, Jorn, et al.
Publicado: (2022)

Contractual Incentives: A Threat to Evidence-Based Medicine?
por: Bull, Scott
Publicado: (2005)

The Added Value of Patient Engagement in Early Dialogue at EMA: Scientific Advice as a Case Study
por: Murphy, Aisling, et al.
Publicado: (2022)

Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
por: Schuller, Y., et al.
Publicado: (2017)

Incentives
por: Smiley, James A.
Publicado: (1949)

The Effect of Incentives and Meta-incentives on the Evolution of Cooperation
por: Okada, Isamu, et al.
Publicado: (2015)

Editorial: Insights in Regulatory Science 2021
por: Sepodes, Bruno, et al.
Publicado: (2022)

Cancer Core Europe: A first step towards a virtual cancer institute in Europe?
por: Celis, Julio E., et al.
Publicado: (2014)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Effectiveness of Mandatory and Incentive-Based Routine Childhood Immunization Programs in Europe: A Systematic Review of the Literature
por: Kuznetsova, Lidia, et al.
Publicado: (2021)

Incentive or Habit Learning in Amphibians?
por: Muzio, Rubén N., et al.
Publicado: (2011)

Shaping science policy in Europe
por: Celis, Julio E., et al.
Publicado: (2014)

Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
por: Harris, Emily
Publicado: (2018)

Managing pollution from antibiotics manufacturing: charting actors, incentives and disincentives
por: Nijsingh, Niels, et al.
Publicado: (2019)

How social preferences provide effort incentives in situations of financial support
por: Knoller, Christian, et al.
Publicado: (2021)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

Selecting effective incentive structures in health care: A decision framework to support health care purchasers in finding the right incentives to drive performance
por: Custers, Thomas, et al.
Publicado: (2008)

Correction to: Managing pollution from antibiotics manufacturing: charting actors, incentives and disincentives
por: Nijsingh, Niels, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q77evkv8llkl75u3knu472f6q2